MARKET

ZIOP

ZIOP

ZIOPHARM Oncolgy
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.498
-0.072
-2.79%
Opening 10:58 09/22 EDT
OPEN
2.560
PREV CLOSE
2.570
HIGH
2.630
LOW
2.490
VOLUME
290.99K
TURNOVER
--
52 WEEK HIGH
5.61
52 WEEK LOW
1.795
MARKET CAP
534.99M
P/E (TTM)
-3.5673
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Ziopharm Oncology Appoints Kevin Buchi to its Board of Directors
– Life Sciences industry veteran; 15-year Cephalon executive, serving progressively  as CFO, COO and then CEO at time of $6.8 billion acquisition by Teva –– Doug Pagán Steps Down from Board of Directors –BOSTON, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”)
GlobeNewswire · 1h ago
Ziopharm Oncology Appoints Four Additional Members to Scientific Advisory Board
BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of four additional members to its Scientific Advisory Board (SAB). The SAB, under the leadership of Carl June, M.D. as chairman, will provide strategic and
GlobeNewswire · 09/15 12:30
Ziopharm Oncology Granted Rare Pediatric Disease Designation for Controlled IL-12 for the Treatment of DIPG
BOSTON, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the investigational treatment
GlobeNewswire · 09/14 13:30
Ziopharm Oncology to Participate in Upcoming Conferences
BOSTON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in two upcoming conferences: H.C. Wainwright 22nd Annual Global Investment Conference Date: Wednesday
GlobeNewswire · 09/10 14:00
ZIOPHARM Oncology (ZIOP) Has Fallen 47% in Last One Year, Underperforms Market
If you are looking for the best ideas for your portfolio you may want to consider some of Miller Value Partners top stock picks. Miller Value Partners, an investment management firm, is bullish on Ziopharm Oncology Inc (NASDAQ:ZIOP) stock. In its Opportunity Equity Q2 2019 investor letter – you can download a copy here – […]
Insider Monkey · 09/07 13:58
ZIOPHARM Oncology EPS in-line
ZIOPHARM Oncology (NASDAQ:ZIOP): Q2 GAAP EPS of -$0.09 in-line. Cash and cash equivalents of $153.5M Press Release
seekingalpha · 08/07 01:20
ZIOPHARM Oncology Q2 Earnings Preview
ZIOPHARM Oncology (NASDAQ:ZIOP) is scheduled to announce Q2 earnings results on Thursday, August 6th, after market close. The consensus EPS Estimate is -$0
seekingalpha · 08/06 02:35
Ziopharm Oncology to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020
BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, August 6, at 4:30 pm EDT to provide a corporate update and discuss financial results for the seco
GlobeNewswire · 07/28 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZIOP stock price target is 5.93 with a high estimate of 7.50 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 226
Institutional Holdings: 106.00M
% Owned: 49.50%
Shares Outstanding: 214.15M
TypeInstitutionsShares
Increased
58
10.03M
New
33
-3.44M
Decreased
32
2.55M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.40%
Pharmaceuticals & Medical Research
-0.83%
Key Executives
Chairman/Independent Director
Scott Tarriff
Chief Executive Officer/Director
Laurence Cooper
Chief Financial Officer
Satyavrat Shukla
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Robert Hadfield
Executive Vice President/General Manager
Jill Buck
Vice President/Director of Investor Relations
David Connolly
Executive Vice President/General Manager
Eleanor De Groot
Executive Vice President/Director of Human Resources
Lynn Ferrucci
Senior Vice President - Finance/Chief Accounting Officer/Treasurer
Kevin Lafond
Director
James Huang
Independent Director
Christopher Bowden
Independent Director
Scott Braunstein
Independent Director
Elan Ezickson
Independent Director
Heidi Hagen
Independent Director
Douglas Pagan
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More

Analyst Price Target

The average ZIOP stock price target is 5.93 with a high estimate of 7.50 and a low estimate of 3.000.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of ZIOPHARM Oncology Inc. stock information, including NASDAQ:ZIOP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZIOP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZIOP stock methods without spending real money on the virtual paper trading platform.